Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages toward an Inflammatory Protumor Phenotype.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
03 2020
Historique:
received: 17 10 2018
revised: 12 07 2019
accepted: 03 01 2020
pubmed: 12 1 2020
medline: 21 10 2020
entrez: 12 1 2020
Statut: ppublish

Résumé

In established tumors, tumor-associated macrophages (TAM) orchestrate nonresolving cancer-related inflammation and produce mediators favoring tumor growth, metastasis, and angiogenesis. However, the factors conferring inflammatory and protumor properties on human macrophages remain largely unknown. Most solid tumors have high lactate content. We therefore analyzed the impact of lactate on human monocyte differentiation. We report that prolonged lactic acidosis induces the differentiation of monocytes into macrophages with a phenotype including protumor and inflammatory characteristics. These cells produce tumor growth factors, inflammatory cytokines, and chemokines as well as low amounts of IL10. These effects of lactate require its metabolism and are associated with hypoxia-inducible factor-1α stabilization. The expression of some lactate-induced genes is dependent on autocrine M-CSF consumption. Finally, TAMs with protumor and inflammatory characteristics (VEGF

Identifiants

pubmed: 31924656
pii: 2326-6066.CIR-18-0749
doi: 10.1158/2326-6066.CIR-18-0749
doi:

Substances chimiques

CSF2 protein, human 0
Cytokines 0
Macrophage Colony-Stimulating Factor 81627-83-0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-395

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Léa Paolini (L)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.

Clément Adam (C)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.

Céline Beauvillain (C)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Laboratoire d'Immunologie et Allergologie, CHU d'Angers, Angers, France.

Laurence Preisser (L)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.

Simon Blanchard (S)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Laboratoire d'Immunologie et Allergologie, CHU d'Angers, Angers, France.

Pascale Pignon (P)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.

Valérie Seegers (V)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Institut de Cancérologie de l'Ouest, Angers, France.

Louise-Marie Chevalier (LM)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Institut de Cancérologie de l'Ouest, Angers, France.

Mario Campone (M)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Institut de Cancérologie de l'Ouest, Angers, France.

Romuald Wernert (R)

Institut de Cancérologie de l'Ouest, Angers, France.

Véronique Verrielle (V)

Institut de Cancérologie de l'Ouest, Angers, France.

Pedro Raro (P)

Institut de Cancérologie de l'Ouest, Angers, France.

Norbert Ifrah (N)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Service des Maladies du Sang, CHU d'Angers, Angers, France.

Vincent Lavoué (V)

Service de Gynécologie-obstétrique, CHU de Rennes, Rennes, France.
UMR INSERM 1242, Université de Rennes, Rennes, France.

Philippe Descamps (P)

Département de Gynécologie, CHU d'Angers, Angers, France.

Alain Morel (A)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Institut de Cancérologie de l'Ouest, Angers, France.

Véronique Catros (V)

CHU de Rennes, Rennes, France; UMR INSERM 991, Rennes, France; CRB Santé de Rennes, Rennes, France.

Guillaume Tcherkez (G)

Research School of Biology, ANU Joint College of Sciences, Australian National University, Canberra, Australian Capital Territory, Australia.

Guy Lenaers (G)

Université d'Angers, Inserm U1083, CNRS U6015, Institut MitoVasc, Angers, France.

Cinzia Bocca (C)

Université d'Angers, Inserm U1083, CNRS U6015, Institut MitoVasc, Angers, France.

Judith Kouassi Nzoughet (J)

Université d'Angers, Inserm U1083, CNRS U6015, Institut MitoVasc, Angers, France.

Vincent Procaccio (V)

Université d'Angers, Inserm U1083, CNRS U6015, Institut MitoVasc, Angers, France.
Département de Biochimie et Génétique, CHU d'Angers, Angers, France.

Yves Delneste (Y)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France.
Laboratoire d'Immunologie et Allergologie, CHU d'Angers, Angers, France.

Pascale Jeannin (P)

Université d'Angers, CHU d'Angers, Inserm U1232, CRCINA, Angers, France. pascale.jeannin@univ-angers.fr.
Laboratoire d'Immunologie et Allergologie, CHU d'Angers, Angers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH